drugset
drugset / Trial / NCT06074016

Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.

NCT06074016 ↗

Phase 1 Completed 8 enrolled Parc de Salut Mar Food and Drug Administration (FDA) · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is a phase I study to evaluate the PBPK of zolmitriptan intranasal versus oral administration.

Timeline

Start
2023-07-12
Primary completion
2023-09-06
Completion
2023-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolmitriptan Small molecule 5 mg Intranasal

Indications

No indication recorded.